In our model, the anti-CCL2 antibody treatment reduces CCL3 expression in MAMs but inhibition rate is only 40% compared with IgG treatment [13], suggesting that factors other than CCL2 from cancer cells and/or tumor microenvironment also involve in CCL3 secretion from MAMs. This evidence concerns the gene CCL3 and cancer.